Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth
Zai Lab Limited's stock surged 105% in a year. Click to explore ZLAB's $2bn revenue goal, key drugs, and strategic ...
Zai Lab (ZLAB) Initiated with a Buy at Scotiabank
Zai Lab (ZLAB – Research Report) received a Buy rating and a $55.00 price target from Scotiabank analyst Louise Chen today. The company’s ...
American Association of Individual Investors5d
Which Is a Better Investment, Recursion Pharmaceuticals, Inc. or Zai Lab Limited Stock?
Learn more about whether Recursion Pharmaceuticals, Inc. or Zai Lab Limited is a better investment based on AAII's A+ ...
Zai Lab announces acceptance of BLA for TIVDAK in cervical cancer
Zai Lab (ZLAB) “announced that China’s National Medical Products Administration has accepted the Biologics License Application for TIVDAK, ...
Zai Lab price target raised to $51 from $44 at JPMorgan
JPMorgan raised the firm’s price target on Zai Lab (ZLAB) to $51 from $44 and keeps an Overweight rating on the shares. The firm updated models ...
Analysts Offer Insights on Healthcare Companies: Zai Lab (ZLAB), Perspective Therapeutics (CATX) and Edesa Biotech (EDSA)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zai Lab (ZLAB – Research Report), Perspective ...
Business Insider16d
Zai Lab initiated with an Outperform at Scotiabank
Scotiabank initiated coverage of Zai Lab (ZLAB) with an Outperform rating and $55 price target The firm says that although geopolitical risk has capped the stock’s upside for years, Zai Lab is ...
ETF Daily News7d
Zai Lab (NASDAQ:ZLAB) Price Target Raised to $51.00
Shares of ZLAB stock opened at $38.20 on Thursday. Zai Lab has a 1 year low of $13.48 and a 1 year high of $39.61. The stock’s 50 day simple moving average is $29.47 and its two-hundred day ...